Matinas Biopharma Holdings Inc Dossier - Source-backed chat

Matinas Biopharma Holdings Inc

MTNBNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.52

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.42Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.4M

Enterprise Value $1.6M

Shares Outstanding 14.7M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Matinas BioPharma is in a critical transitional phase, having pivoted from internal R&D to actively seeking strategic partnerships or monetization opportunities for its lead clinical asset, MAT2203 (an oral formulation of amphotericin B built on its lipid nanocrystal platform). Following a terminated partnership negotiation in late 2024, the company executed an 80% workforce reduction and paused clinical development to preserve cash. While MAT2203 has demonstrated robust Phase 2 data and has a clear Phase 3 regulatory path (ORALTO trial design agreed with the FDA), Matinas faces severe going-concern risks, a low cash balance of $2.4 million as of March 31, 2026, and a notice of non-compliance from the NYSE American due to low stockholders' equity. The stock represents a high-risk, binary option on the successful monetization or partnering of MAT2203.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0525%

Matinas fails to secure a partner or buyer for MAT2203 before its cash reserves are fully depleted. The NYSE American rejects its compliance plan, leading to delisting. Ultimately, the company is forced to wind down operations and liquidate assets, resulting in near-total loss for common stockholders.

Base CaseCentral scenario

$0.7550%

The company continues to operate at a minimal cash burn rate while negotiating with potential partners. It may execute highly dilutive micro-cap equity raises under its $150 million shelf registration to extend its runway, or obtain a temporary reprieve from the NYSE American, keeping the stock range-bound as a speculative hold.

Bull CaseUpside scenario

$2.5025%

Matinas successfully secures a global licensing partner or sells the MAT2203 asset to a well-capitalized pharmaceutical company. This transaction provides substantial upfront non-dilutive cash, validates the LNC platform, and funds the Phase 3 ORALTO trial, driving a significant re-rating of the stock.

Scenarios reflect our research view at the research date.

Key Investment Merits

MAT2203 is a Phase 3-ready, oral, non-toxic formulation of amphotericin B, a gold-standard fungicidal agent with a low risk of resistance.
MAT2203 has received multiple FDA designations, including QIDP, Fast Track, and Orphan Drug, which provide potential for extended market exclusivity.
The proprietary Lipid Nanocrystal (LNC) platform has broad potential applicability for oral delivery of other toxic or poorly bioavailable small molecules and nucleic acids.

Key Investment Risks

Severe going-concern risk with only $2.4 million in cash and cash equivalents as of March 31, 2026.
NYSE American non-compliance notice due to stockholders' equity falling below the $6.0 million threshold, creating delisting risk.
High dependency on a single binary event (partnering or selling MAT2203) to avoid company wind-down.
Substantial dilution risk from potential future equity issuances under the $150 million shelf registration or conversion of outstanding preferred stock and warrants.

Thesis Invalidation Triggers

Rejection of the company's compliance plan by the NYSE American, triggering immediate delisting proceedings.
Official announcement of the termination of strategic alternative evaluations and initiation of a company wind-down or bankruptcy filing.
Complete depletion of cash reserves without securing any additional financing or partnership upfront payments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.